Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALPL | P05186 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754730 | 0.91 | MEN1 (0.61) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL25754679 | 0.88 | SMN1; SMN2 (0.64) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL25754747 | 0.87 | ALPL (0.55) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL23833756 | 0.86 | POLB (0.56) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL25754729 | 0.86 | LMNA (0.67) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL25754726 | 0.86 | IDH1 (0.61) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL25754684 | 0.86 | HPGD (0.62) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL25754741 | 0.84 | HPGD (0.57) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL23833741 | 0.84 | RECQL (0.67) | POLBALPLLMNAALDH1A1HPGD | |
| SCHEMBL7527610 | 0.82 | SMN1; SMN2 (0.65) | POLBALPLLMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | POLB 1494/4885ALPL 3721/4885LMNA 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.